THERMO FISHER SCIENTIFIC INC.
TMOAPI behind this page
TMO Q3 2025 request
Playground key active
/api/financials?ticker=TMO&year=2025&quarter=3
Pick an endpoint and run the request.Income Statement
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Revenue | 11,122 | 10,598 | +4.9% |
Show Product Lines breakouts |
|||
| Consumables | 4,679 | 4,379 | +6.9% |
| Instruments | 1,811 | 1,769 | +2.4% |
| Product | 6,489 | 6,148 | +5.5% |
| Service | 4,633 | 4,450 | +4.1% |
Show Business Segments breakouts |
|||
| Analytical Instruments | 1,847 | 1,776 | +4.0% |
| Analytical Instruments · Chemical analysis | 320 | 332 | -3.6% |
| Analytical Instruments · Chromatography and mass spectrometry | 841 | 802 | +4.9% |
| Analytical Instruments · Electron microscopy | 732 | 675 | +8.4% |
| Analytical Instruments · Material Reconciling Items | 46 | 32 | +43.8% |
| Analytical Instruments · Operating Segments | 1,893 | 1,808 | +4.7% |
| Laboratory Products and Biopharma Services | 5,927 | 5,701 | +4.0% |
| Laboratory Products and Biopharma Services · Clinical research | 2,019 | 1,956 | +3.2% |
| Laboratory Products and Biopharma Services · Intersubsegment Eliminations | -226 | -216 | -4.6% |
| Laboratory Products and Biopharma Services · Laboratory products | 594 | 614 | -3.3% |
| Laboratory Products and Biopharma Services · Material Reconciling Items | 43 | 39 | +10.3% |
| Laboratory Products and Biopharma Services · Operating Segments | 5,970 | 5,740 | +4.0% |
| Laboratory Products and Biopharma Services · Pharma services | 1,722 | 1,647 | +4.6% |
| Laboratory Products and Biopharma Services · Research and safety market channel | 1,861 | 1,739 | +7.0% |
| Life Sciences Solutions | 2,194 | 2,009 | +9.2% |
| Life Sciences Solutions · BioProduction | 817 | 680 | +20.1% |
| Life Sciences Solutions · Biosciences | 1,023 | 1,006 | +1.7% |
| Life Sciences Solutions · Genetic sciences | 720 | 701 | +2.7% |
| Life Sciences Solutions · Material Reconciling Items | 394 | 378 | +4.2% |
| Life Sciences Solutions · Operating Segments | 2,588 | 2,387 | +8.4% |
| Life Sciences Solutions · Other | 28 | -1 | +2900.0% |
| Specialty Diagnostics | 1,154 | 1,111 | +3.9% |
| Specialty Diagnostics · Clinical diagnostics | 283 | 266 | +6.4% |
| Specialty Diagnostics · Healthcare market channel | 444 | 453 | -2.0% |
| Specialty Diagnostics · ImmunoDiagnostics | 230 | 212 | +8.5% |
| Specialty Diagnostics · Intersubsegment Eliminations | -70 | -75 | +6.7% |
| Specialty Diagnostics · Material Reconciling Items | 20 | 18 | +11.1% |
| Specialty Diagnostics · Microbiology | 162 | 159 | +1.9% |
| Specialty Diagnostics · Operating Segments | 1,174 | 1,129 | +4.0% |
| Specialty Diagnostics · Transplant diagnostics | 125 | 114 | +9.6% |
Show Geography breakouts |
|||
| Asia Pacific | 2,013 | 1,923 | +4.7% |
| Europe | 3,005 | 2,686 | +11.9% |
| North America | 5,689 | 5,591 | +1.8% |
| Other regions | 415 | 397 | +4.5% |
Show Consolidation Items breakouts |
|||
| Intersegment Elimination | -503 | -467 | -7.7% |
| Material Reconciling Items | 503 | 467 | +7.7% |
| Operating Segments | 11,626 | 11,065 | +5.1% |
| Cost of Revenue (Q) | — | — | — |
Show Product Lines breakouts |
|||
| Product | 3,319 | 3,170 | +4.7% |
| Service | 3,220 | 3,100 | +3.9% |
| Selling, General & Administrative | 2,162 | 2,098 | +3.1% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 307 | 310 | -1.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 582 | 588 | -1.0% |
| Life Sciences Solutions · Operating Segments | 470 | 475 | -1.1% |
| Specialty Diagnostics · Operating Segments | 175 | 178 | -1.7% |
| Research & Development | 346 | 346 | 0.0% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 144 | 134 | +7.5% |
| Laboratory Products and Biopharma Services · Operating Segments | 14 | 16 | -12.5% |
| Life Sciences Solutions · Operating Segments | 136 | 141 | -3.5% |
| Specialty Diagnostics · Operating Segments | 42 | 44 | -4.5% |
| Restructuring And Other Costs Income Net | 135 | 45 | +200.0% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 54 | — | — |
| Laboratory Products and Biopharma Services · Operating Segments | 39 | — | — |
| Life Sciences Solutions · Operating Segments | 78 | — | — |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -36 | — | — |
| Material Reconciling Items | 135 | 45 | +200.0% |
| Total Costs & Expenses | 9,182 | 8,759 | +4.8% |
| Operating Income | 1,941 | 1,838 | +5.6% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 429 | 451 | -4.9% |
| Laboratory Products and Biopharma Services · Operating Segments | 868 | 773 | +12.3% |
| Life Sciences Solutions · Operating Segments | 968 | 845 | +14.6% |
| Specialty Diagnostics · Operating Segments | 321 | 293 | +9.6% |
Show Consolidation Items breakouts |
|||
| Operating Segments | 2,587 | 2,362 | +9.5% |
| Interest Income | 234 | 277 | -15.5% |
| Interest Expense | -347 | -356 | +2.5% |
| Other Non-Operating Income (Expense) | -2 | -16 | +87.5% |
| Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments | 1,826 | 1,742 | +4.8% |
| Income Tax Expense (Benefit) | -207 | -99 | -109.1% |
| Income Loss From Equity Method Investments | 2 | -14 | +114.3% |
| Net Income | 1,621 | 1,629 | -0.5% |
| Net Income Loss Attributable To Noncontrolling Interest | 5 | — | — |
| Net Income | 1,616 | 1,630 | -0.9% |
| EPS (Basic) | 4.28 | 4.26 | +0.5% |
| EPS (Diluted) | 4.27 | 4.25 | +0.5% |
| Wtd Avg Shares (Basic) | 378 | 382 | -1.0% |
| Wtd Avg Shares (Diluted) | 378 | 384 | -1.6% |
| Cost of Revenue (Q) | — | — | — |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 975 | 878 | +11.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 4,622 | 4,488 | +3.0% |
| Life Sciences Solutions · Operating Segments | 961 | 907 | +6.0% |
| Specialty Diagnostics · Operating Segments | 682 | 668 | +2.1% |
| Comprehensive Income | 1,612 | 1,566 | +2.9% |
| Gain Loss On Investments | 8 | -4 | +300.0% |
Balance Sheet
| Metric | Q3 2025 | Q3 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,982 | — | — |
| Short-Term Investments | 1,564 | 2,000 | -21.8% |
| Accounts Receivable | 8,911 | 8,255 | +7.9% |
| Inventory | 5,745 | — | — |
| Contract With Customer Asset Net Current | 1,620 | — | — |
| Other Assets Current | 2,472 | 1,911 | +29.4% |
| Total Current Assets | 22,295 | 23,783 | -6.3% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 10,177 | 9,412 | +8.1% |
| Other Non-Current Assets | 5,019 | 4,180 | +20.1% |
| Goodwill | 49,287 | — | — |
| Total Assets | 103,020 | 100,364 | +2.6% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 3,189 | 2,905 | +9.8% |
| Laboratory Products and Biopharma Services · Operating Segments | 6,763 | 6,438 | +5.0% |
| Life Sciences Solutions · Operating Segments | 3,552 | 3,211 | +10.6% |
| Specialty Diagnostics · Operating Segments | 1,307 | 1,234 | +5.9% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 88,209 | 86,575 | +1.9% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 16,242 | 16,262 | -0.1% |
| Current Liabilities | |||
| Debt Current | 3,823 | 4,116 | -7.1% |
| Accounts Payable | 3,120 | 2,606 | +19.7% |
| Employee Related Liabilities Current | 1,884 | 1,823 | +3.3% |
| Deferred Revenue (Current) | 2,852 | — | — |
| Other Liabilities Current | 3,209 | 3,393 | -5.4% |
| Total Current Liabilities | 14,888 | 14,601 | +2.0% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 842 | 1,123 | -25.0% |
| Other Non-Current Liabilities | 4,278 | 4,343 | -1.5% |
| Long-Term Debt | 35,484 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Commercial Paper | 500 | — | — |
| Other | 1 | — | — |
| Senior Notes | 34,983 | — | — |
| Contract With Customer Liability Noncurrent | 1,159 | — | — |
| Other Liabilities | |||
| Long Term Debt And Capital Lease Obligations | 31,857 | 31,197 | +2.1% |
| Redeemable Noncontrolling Interest Equity Carrying Amount | 129 | 127 | +1.6% |
| Stockholders' Equity | |||
| Common Stock | 445 | 444 | +0.2% |
| Additional Paid In Capital Common Stock | 18,330 | 17,831 | +2.8% |
| Retained Earnings | 57,354 | 51,421 | +11.5% |
| Treasury Stock Common Value | -22,310 | -18,227 | -22.4% |
| Accumulated Other Comprehensive Income | -2,801 | -2,477 | -13.1% |
| Total Stockholders' Equity | 51,018 | 48,992 | +4.1% |
| Minority Interest | 7 | -20 | +135.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 51,024 | 48,972 | +4.2% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -265 | — | — |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -23 | — | — |
| Accumulated Other Comprehensive Income | -2,801 | -2,477 | -13.1% |
| Accumulated Translation Adjustment | -2,512 | — | — |
| Additional Paid In Capital | 18,330 | 17,831 | +2.8% |
| Common Stock | 445 | 444 | +0.2% |
| Noncontrolling Interest | 7 | -20 | +135.0% |
| Parent | 51,018 | 48,992 | +4.1% |
| Retained Earnings | 57,354 | 51,421 | +11.5% |
| Treasury Stock Common | -22,310 | -18,227 | -22.4% |
| Total Liabilities & Equity | 103,020 | 100,364 | +2.6% |
Cash Flow Statement
| Metric | YTD Q3 2025 | YTD Q3 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation | 758 | 852 | -11.0% |
Show Business Segments breakouts |
|||
| Analytical Instruments · Operating Segments | 76 | 76 | 0.0% |
| Laboratory Products and Biopharma Services · Operating Segments | 439 | 534 | -17.8% |
| Life Sciences Solutions · Operating Segments | 177 | 171 | +3.5% |
| Specialty Diagnostics · Operating Segments | 68 | 72 | -5.6% |
| Amortization Of Intangible Assets | 1,294 | 1,514 | -14.5% |
Show Consolidation Items breakouts |
|||
| Material Reconciling Items | 1,294 | 1,514 | -14.5% |
| Deferred Income Taxes | -728 | -1,007 | +27.7% |
| Stock-Based Compensation | 226 | 222 | +1.8% |
| Other Non-Cash Items | 315 | 254 | +24.0% |
| Increase Decrease In Operating Capital Excluding Deferred Taxes | -2,255 | -973 | -131.8% |
| Net Cash from Operations | 4,361 | 5,377 | -18.9% |
| Investing Activities | |||
| Capital Expenditures | -1,060 | -920 | -15.2% |
| Proceeds From Sale Of Property Plant And Equipment | 17 | 40 | -57.5% |
| Proceeds From Payments For Cross Currency Interest Rate Swap Interest Settlements | 218 | 203 | +7.4% |
| Payments To Acquire Businesses Net Of Cash Acquired | -4,037 | -3,132 | -28.9% |
| Payments To Acquire Investments | -351 | -2,065 | +83.0% |
| Proceeds From Sale Maturity And Collections Of Investments | 254 | 9 | +2722.2% |
| Other Investing Activities | 20 | 5 | +300.0% |
| Net Cash from Investing | -4,938 | -5,861 | +15.7% |
| Financing Activities | |||
| Proceeds From Issuance Of Long Term Debt | 2,840 | 1,204 | +135.9% |
| Repayments Of Long Term Debt | -1,625 | -1,107 | -46.8% |
| Proceeds From Issuance Of Commercial Paper | 1,095 | — | — |
| Repayments Of Commercial Paper | -597 | — | — |
| Share Repurchases | -2,963 | -3,000 | +1.2% |
| Payments Of Dividends Common Stock | -474 | -434 | -9.2% |
| Proceeds From Payments For Other Financing Activities | -1 | 212 | -100.5% |
| Net Cash from Financing | -1,725 | -3,126 | +44.8% |
| Supplemental | |||
| Unpaid Capital Expenditures | 163 | 190 | -14.2% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 273 | 182 | +50.0% |
| Net Change in Cash | -2,029 | -3,427 | +40.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 2,011 | 4,670 | -56.9% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.